DickSIM
Prima o poi....ci becco!
Messaggio da NICOX !!!!!!!!!!
Le attestazioni da Fineco e PNB sono finalmente arrivate !!!!!!!!!!!!!
TUTTO OK !!!!!!!!!!!!!!!!!
MICHELEEEEEEEEEEEEEE ,,,,, FALLI NERI !!!!!!!!!!!!!!!!
NicOx : Garufi ... e la Rivoluzione Pharma
- Creatore Discussione Yesod
- Data di Inizio
- Stato
acqua+
ONDA NITRICA
DickSIM
Prima o poi....ci becco!
Dickkkkkkkkkkk ,,,, pensavo a qlc di meglio
mi son rifatto sul tuo......
sustazz era titubante,,,,,,
DickSIM
Prima o poi....ci becco!
San Mateo, CA-based Bayhill Therapeutics is pocketing a $25 million upfront fee and stands to gain up to $325 million in milestones from a new licensing deal with Genentech covering its early-stage Type 1 diabetes therapy.
"BHT-3021 represents a truly novel approach to treating type 1 diabetes," said Bayhill CEO Mark W. Schwartz, PhD. "We believe this collaboration with Genentech reflects the significant potential of our approach to antigen specific tolerance, and will allow us to accelerate and expand the development of BHT-3021, while continuing to develop additional products from our BHT-DNA platform."
In the deal Bayhill Therapeutics will be responsible for completing an ongoing Phase I/II study before handing the development program over to Genentech, Roche's biologics arm. Genentech will reimburse Bayhill for its study and the biotech company has the right to opt in on future development work while retaining co-promotion rights in the U.S.
"The ultimate goal for treatment of autoimmune disease is antigen specific therapy", commented Lawrence Steinman M.D., the founder, director and chairman of Bayhill's Scientific Advisory Board. "Genentech has long been an innovator in immunology based therapies, making it a strong collaborator for BHT-3021."
"BHT-3021 represents a truly novel approach to treating type 1 diabetes," said Bayhill CEO Mark W. Schwartz, PhD. "We believe this collaboration with Genentech reflects the significant potential of our approach to antigen specific tolerance, and will allow us to accelerate and expand the development of BHT-3021, while continuing to develop additional products from our BHT-DNA platform."
In the deal Bayhill Therapeutics will be responsible for completing an ongoing Phase I/II study before handing the development program over to Genentech, Roche's biologics arm. Genentech will reimburse Bayhill for its study and the biotech company has the right to opt in on future development work while retaining co-promotion rights in the U.S.
"The ultimate goal for treatment of autoimmune disease is antigen specific therapy", commented Lawrence Steinman M.D., the founder, director and chairman of Bayhill's Scientific Advisory Board. "Genentech has long been an innovator in immunology based therapies, making it a strong collaborator for BHT-3021."
Netzach
Forumer storico
sustazz
Nuovo forumer
mi son rifatto sul tuo......
No ero sicuro ma volevo condividere la newss con Acqua infatti eravamo al telefono in quel momento
Ciaoooooooooooooooooo !!!!!!!!!!!!!!!!!!!!!
DickSIM
Prima o poi....ci becco!
- Stato